LAVIPHARM S.A. NA EO 1 (BXA0) — Net Asset Quality Index
LAVIPHARM S.A. NA EO 1 (BXA0) has a Net Asset Quality Index of 42.2% as of December 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €125.48 Million minus total liabilities of €72.52 Million yields net assets of €52.97 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are LAVIPHARM S.A. NA EO 1's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
LAVIPHARM S.A. NA EO 1 Net Asset Quality Index Over Time (2021–2024)
This chart shows how LAVIPHARM S.A. NA EO 1's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the index stands at 42.2%, representing net assets of €52.97 Million against total assets of €125.48 Million EUR. See BXA0 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for LAVIPHARM S.A. NA EO 1 from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see LAVIPHARM S.A. NA EO 1 (BXA0) market capitalisation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 42.2% | €52.97 Million | €125.48 Million | €72.52 Million | ▲ +4.9 pp |
| 2023 | 37.3% | €42.77 Million | €114.79 Million | €72.02 Million | ▲ +2.0 pp |
| 2022 | 35.3% | €40.31 Million | €114.17 Million | €73.86 Million | ▲ +54.2 pp |
| 2021 | -18.8% | €-9.94 Million | €52.74 Million | €62.68 Million | — |